Zaloguj Zarejestruj się zadarmo

Adma Biologics Inc organizacji SMA 200

Jaka jest wartość SMA 200 organizacji Adma Biologics Inc?

Wartość SMA 200 organizacji Adma Biologics Inc to $10 +42.12%

Jaka jest definicja SMA 200?



SMA 200 to średnia cena akcji z ostatnich 200 dni obliczona jako nieważona średnia z 200 ostatnich cen zamknięcia akcji.

Simple moving average of 200 days for a stock is an unweighted moving average over the past 200 days. Moving averages will always exhibit a lag and the longer the period used for averaging the greater the lag will be. Because of the large amounts of data considered when calculating a long-term moving average, it takes a considerable amount of movement in the market to cause the moving average to change its course.

Using a moving average to confirm a trend in price is one of the most basic, yet effecting ways of using the indicator. Moving averages take into account what has already happened and a whole range of past events, which makes them such a good technical analysis tool for trend confirmations. Generally, a long-term moving average that is clearly on the upswing is a confirmation of a bullish trend. Conversely, a long-term moving average that is clearly on the downswing is a confirmation of a bearish trend.

SMA 200 firm w Health Care sektor na NASDAQ w porównaniu do Adma Biologics Inc

Czym się zajmuję organizacja Adma Biologics Inc?

adma is a late-stage biopharmaceutical company that develops, manufactures and intends to commercialize specialty plasma-based biologics for the treatment and prevention of primary immune deficiency disease (pidd) and certain infectious diseases. adma's mission is to develop and commercialize plasma-derived, human immune globulins targeted to niche patient populations for the treatment and prevention of certain infectious diseases. the target patient populations include immune-compromised individuals who suffer from an underlying immune deficiency disease, or who may be immune-compromised for medical reasons. adma’s lead product candidate, ri-002, has completed a phase iii clinical trial in patients with pidd and has met the primary endpoint. a bla for ri-002 was accepted by the fda on september 18, 2015. the company has received u.s. patent 9,107,906. for more information, please visit the company's website at www.admabiologics.com.

Firmy z sma 200 podobne do Adma Biologics Inc